IDSA GUIDELINES Bundle (free trial)

Chronic Kidney Disease in HIV-Infected Patients

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/418521

Contents of this Issue

Navigation

Page 9 of 15

Î IDSA suggests using ACE inhibitors or ARBs to treat proteinuric nephropathy in children with HIV infection and suggests their use as first-line therapy for hypertension in these children. Because HIV- infected children with proteinuria may be at greater risk for salt wasting and prone to dehydration, ACE inhibitors and ARBs should be used with caution in children (W-VL). Î IDSA suggests that corticosteroids NOT be used in children with HIVAN (W-VL). Table 4. Dosing of Antiretroviral Drugs for HIV-Infected Adults With CKD or ESRD Antiretroviral Drug and Dosing Category Dosage Comments Nucleoside reverse transcriptase inhibitors (NRTIs) Zidovudine CrCl ≥15 mL/min 300 mg PO bid CrCl <15 mL/min, HD, or peritoneal dialysis (PD) 100 mg PO q6-8h or 300 mg daily Based on longer intracellular half-life Lamivudine CrCl ≥50 mL/min 150 mg PO bid/300 mg PO daily CrCl 30-49 mL/min 150 mg PO daily CrCl 15-29 mL/min 150 mg PO first dose, then 100 mg PO daily CrCl 5-14 mL/min 150 mg PO first dose, then 50 mg PO daily To avoid using the liquid formulation and because of the favorable safety profile, some recommend using the lowest available tablet dose of 100 mg (lamivudine hepatitis B formulation) or 150 mg (lamivudine) daily in advanced renal disease. CrCl <5 mL/min, HD, or PD 50 mg PO first dose, then 25 mg PO daily Abacavir All CrCl 300 mg PO bid/600 mg PO daily Receiving HD No adjustment a Receiving PD Unknown, use with caution Treatment 8

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Chronic Kidney Disease in HIV-Infected Patients